Anthem Blue Cross California Commercial Clinical Policy

Anthem Blue Cross California Duopa (carbidopa and levodopa enteral suspension) Form


Effective Date

09/18/2023

Last Reviewed

08/18/2023

Original Document

  Reference



Overview

This document addresses the use of Duopa (carbidopa and levodopa enteral suspension) infusion for the treatment of late-stage Parkinson’s disease (PD) in individuals who have poor function (as defined by more “off” periods and fluctuations between “on/off” periods and/or dyskinesias) despite optimal medical therapy.

Parkinson's Disease (PD) Overview

PD is a progressive neurodegenerative disorder associated with motor complications such as tremor, bradykinesia, and rigidity. The decision to initiate pharmacologic therapy for the management of symptoms associated with PD is determined by the degree to which the individual is functionally impaired and influenced by a variety of individual and medication-related factors. Treatment is individualized and combination therapy is often employed to manage symptoms and reduce “off” episodes (refers to “end-of-dose wearing off” and unpredictable “on/off” episodes).

Coding

  • HCPCS
    • J7340
    • Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml

ICD-10 Diagnosis

  • G20
    • Parkinson's disease

Document History

Revised: 08/18/2023

Want to learn more?